|
|
|
12 October 2018
By Maynard Paton |
Update on Bioventix (BVXP). |
Event: Preliminary results for the year to 30 June 2018 published 08 October 2018. |
Summary: The antibody specialist delivered yet another set of record results, with my number-crunching indicating underlying growth of 20%. However, I was disappointed to discover early sales of the important new troponin product had been below expectations — and may have left the lofty P/E valuation open to debate (at least for now). Still, the business continues to exhibit magnificent accounts while a special dividend for the third consecutive year underpins the board’s confidence. I continue to hold.
|
|
|
|
|
|
08 October 2018
By Maynard Paton |
Event: Interim results for the six months to 30 June 2018 published 28 September 2018. |
Summary: These figures were not as good as I had hoped. The lowest first-half sales for seven years created a not-insignificant operating loss and left cash flow dependent on tax refunds. Still, the geoscience software specialist talked of a stronger second half and I remain hopeful the accounts will eventually showcase the high margins and expanding revenue the directors continue to predict. For the time being, I just have to trust a stronger oil price can one day tempt GTC’s customers to increase their spending. I continue to hold.
|
|
|
|
|
|
08 October 2018
By Maynard Paton
|
I have written another article for SharePad.
|
This time my screening has short-listed Character (CCT) as a possible longer-term investment.
|
The attraction here is a quite extraordinary story about buybacks.
|
You see, since 2006, this small-cap has bought back shares every year to reduce its overall share count by a huge 60%.
|
What’s more, the purchases have been an exemplary use of surplus cash. The average price paid was 143p, and the shares currently trade above 500p.
|
Needless to say, I now ask myself whether further significant buybacks at Character should prompt us to invest, too.
|
|
|
|
|
|
|